These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29980281)

  • 1. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
    Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
    Xing D; Fadare O
    Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.
    Weberpals JI; Lo B; Duciaume MM; Spaans JN; Clancy AA; Dimitroulakos J; Goss GD; Sekhon HS
    Clin Cancer Res; 2017 Aug; 23(15):4501-4510. PubMed ID: 28377483
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic Mutation Profiling in Premalignant Lesions of Vulvar Squamous Cell Carcinoma.
    Zięba S; Pouwer AW; Kowalik A; Zalewski K; Rusetska N; Bakuła-Zalewska E; Kopczyński J; Pijnenborg JMA; de Hullu JA; Kowalewska M
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
    Trietsch MD; Spaans VM; ter Haar NT; Osse EM; Peters AA; Gaarenstroom KN; Fleuren GJ
    Gynecol Oncol; 2014 Oct; 135(1):149-55. PubMed ID: 25072932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome.
    Tessier-Cloutier B; Pors J; Thompson E; Ho J; Prentice L; McConechy M; Aguirre-Hernandez R; Miller R; Leung S; Proctor L; McAlpine JN; Huntsman DG; Gilks CB; Hoang LN
    Mod Pathol; 2021 Feb; 34(2):508-518. PubMed ID: 32792599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiles of Japanese patients with vulvar squamous cell carcinoma.
    Fujii E; Kato MK; Yamaguchi M; Higuchi D; Koyama T; Komatsu M; Hamamoto R; Ishikawa M; Kato T; Kohno T; Shiraishi K; Yoshida H
    Sci Rep; 2024 Jun; 14(1):13058. PubMed ID: 38844774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Landscape of Vulvar Squamous Cell Carcinoma.
    Carreras-Dieguez N; Guerrero J; Rodrigo-Calvo MT; Ribera-Cortada I; Trias I; Jares P; López Del Campo R; Saco A; Munmany M; Marimon L; Ferrando M; Vega N; Del Pino M; Torné A; Ordi J; Rakislova N
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
    Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
    Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.
    Clancy AA; Spaans JN; Weberpals JI
    Ann Oncol; 2016 Sep; 27(9):1696-705. PubMed ID: 27329249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE
    Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
    Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
    Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies.
    Zięba S; Chechlińska M; Kowalik A; Kowalewska M
    Gynecol Oncol; 2020 Aug; 158(2):498-506. PubMed ID: 32522421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
    Dongre HN; Elnour R; Tornaas S; Fromreide S; Thomsen LCV; Kolseth IBM; Nginamau ES; Johannessen AC; Vintermyr OK; Costea DE; Bjørge L
    Acta Obstet Gynecol Scand; 2024 Jan; 103(1):165-175. PubMed ID: 37840151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
    Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
    J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.